Sökning: WFRF:(Xanthoulis Panagiotis) > Predictors of long-...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04623nam a2200457 4500 | |
001 | oai:DiVA.org:uu-497492 | |
003 | SwePub | |
008 | 230228| | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4974922 URI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a vet2 swepub-contenttype |
072 | 7 | a ovr2 swepub-publicationtype |
100 | 1 | a Isaksson, Johanu Uppsala universitet,Centrum för klinisk forskning, Gävleborg,Institutionen för immunologi, genetik och patologi,Johan Botling4 aut0 (Swepub:uu)johis237 |
245 | 1 0 | a Predictors of long-term survival and recurrence patterns after definitive chemoradiotherapy in stage III NSCLC – a multicenter cohort study from Mid Sweden |
338 | a print2 rdacarrier | |
520 | a Background: Stage III NSCLC is heterogeneous but often recurs despite intensive treatment with curative intent. Clinical tools to predict the risk and pattern of recurrence and long-term survival in individual patients are largely lacking. Methods: NSCLC stage III patients (N=193) treated 2009-2018 with definitive, curatively intended chemoradiotherapy (CRT, 60Gy+) were retrospectively identified from three healthcare regions in Mid Sweden. Outcome variables included overall survival (OS), progression-free survival (PFS) and recurrence patterns. Results: Median follow-up of patients alive was 52 months. 1, 2 and 5-year OS was 80%, 63% and 34% with a mOS of 32 months. Pre-treatment serum inflammatory markers were associated with inferior OS, including leukocyte count > 10 (HR 1.58, 95% CI 1.08-2.31, p=0.018) and CRP > 5 (HR 1.81, 95% CI 1.16-2.83, p=0.009). CRP remained independently associated with OS in multivariable analysis, HR 1.67 (1.05-2.65, p=0.029). No other pre-treatment variable was significantly associated with OS. Progressive disease (PD) was documented in 65% of patients after a median time of 9.5 months, 96% within 3 years from CRT, and was typically either distant or locoregional (12% mixed). Distant PD developed earlier (6.3 months) than locoregional PD (11.5 months; p=0.052). N3 disease (OR 2.7, 95% CI 1.2-6.3,; p=0.022) and presence of driver mutations (OR 4.6, 95% CI 1.5-14.0; p=0.0076) increased the risk of distant PD, while ≥2 concurrent chemotherapy courses was protective of locoregional PD (OR 0.38, 9% CI 0.1-1.0; p=0.049). Brain metastases were the first indication of PD in 22 patients (12%) and were in all cases isolated without synchronous extracranial PD. A post-CRT 18F-FDG-PET SUVmax of ≥7 was associated with a shorter time to PD (HR 0.41, 95% CI 0.21-0.79, p=0.008). Conclusions: The study reinforces the prognostic role of systemic inflammation in stage III NSCLC and provides clinically useful indicators of relapse pattern as a basis for rational disease monitoring following CRT. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a Oncology | |
653 | a Onkologi | |
700 | 1 | a Xanthoulis, Panagiotis4 aut |
700 | 1 | a Broström, Erikau Uppsala universitet,Lung- allergi- och sömnforskning4 aut0 (Swepub:uu)eribr175 |
700 | 1 | a Börjesson, Rebecka4 aut |
700 | 1 | a Olsson, Erik4 aut |
700 | 1 | a Willén, Linda,d 1979-u Uppsala universitet,Centrum för klinisk forskning, Gävleborg4 aut0 (Swepub:uu)linwa756 |
700 | 1 | a Isacsson, Ulf4 aut |
700 | 1 | a Sobrino, Pierre4 aut |
700 | 1 | a Hansen, Tomasu Uppsala universitet,Radiologi4 aut0 (Swepub:uu)tohan227 |
700 | 1 | a Mouratidou, Valentina4 aut |
700 | 1 | a Holgersson, Georg4 aut |
700 | 1 | a Bergqvist, Michael4 aut |
700 | 1 | a Tsakonas, Georgios4 aut |
700 | 1 | a Ekman, Simon4 aut |
700 | 1 | a Micke, Patricku Uppsala universitet,Science for Life Laboratory, SciLifeLab,Institutionen för immunologi, genetik och patologi,Institutionen för medicinsk biokemi och mikrobiologi4 aut0 (Swepub:uu)patmi676 |
700 | 1 | a Lamberg, Kristinau Uppsala universitet,Lung- allergi- och sömnforskning4 aut0 (Swepub:uu)krila642 |
700 | 1 | a Botling, Johanu Uppsala universitet,Science for Life Laboratory, SciLifeLab,Institutionen för immunologi, genetik och patologi4 aut0 (Swepub:uu)johanbot |
700 | 1 | a Lindskog, Magnusu Uppsala universitet,Institutionen för immunologi, genetik och patologi4 aut0 (Swepub:uu)magli409 |
710 | 2 | a Uppsala universitetb Centrum för klinisk forskning, Gävleborg4 org |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-497492 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy